Ultrasonographic markers and preoperative CA-125 to distinguish between borderline ovarian tumors and stage I ovarian cancer

2012 ◽  
Vol 92 (3) ◽  
pp. 285-292 ◽  
Author(s):  
Dimitrios Zacharakis ◽  
Nikolaos Thomakos ◽  
Ioannis Biliatis ◽  
Alexandros Rodolakis ◽  
Maria Simou ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Ovarian Tumors ◽  
Stage I ◽  
Ca 125 ◽  
Borderline Ovarian Tumors

Is CA-125 an additional marker to ultrasonographic features for distinguishing between borderline ovarian tumors and stage I ovarian cancer?

2012 ◽  
Vol 125 ◽  
pp. S90
Author(s):  
D. Zacharakis ◽  
N. Thomakos ◽  
A. Rodolakis ◽  
M. Simou ◽  
D. Haidopoulos ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Ovarian Tumors ◽  
Stage I ◽  
Ca 125 ◽  
Borderline Ovarian Tumors ◽  
Additional Marker

scholarly journals Determination of Serum CA125 and evaluate its efficiency as screening tool For Early Detection of Ovarian Tumors

2015 ◽  
Vol 12 (1) ◽  
pp. 55-62
Author(s):  
Baghdad Science Journal
Keyword(s):  
Ovarian Cancer ◽  
Early Detection ◽  
Screening Tool ◽  
Stage I ◽  
Ca 125 ◽  
Benign Tumors ◽  
Cancer Antigen 125 ◽  
Ovarian Cancers ◽  
Serum Ca125 ◽  
Low Sensitivity

Epithelial ovarian cancer is the leading cause of cancer deaths in women. To date, an effective screening tool for ovarian cancer has not been identified Several clinical and biological factors including serum cancer antigen 125 (CA- 125) have been assessed for prognostic and predictive relevance CA-125 is an epithelial marker derived from coelomic epithelium. It is elevated in 90% of advanced ovarian cancers and in 50% of early ovarian cancers while 20% of ovarian cancers have low or no expression of CA- 125 CA-125 concentrations were measured by Mini Vidas test (VIDAS CA125 II / BIOMERIEUX / France). The median CA-125 levels were significantly higher in the sera of ovarian cancer patients than in those with benign tumors and in healthy controls. However in correlation with stages the results showed that Patients with stage II have highly significant differences in level of serum CA125 compare with stage I in and stage III.CA125 showed low sensitivity to detect stage I carcinoma of the ovary which limits its value as an initial screening tool therefore combining of CA125 with other markers might enable improved early detection of ovarian cancer as compared with use of this marker alone.

Resection Guided by Antibodies (REGAJ) a Reappraisal after 10 Years

1998 ◽  
Vol 13 (4) ◽  
pp. 221-223 ◽  
Author(s):  
W. Jäger ◽  
S. Ackermann
Keyword(s):  
Ovarian Cancer ◽  
Monoclonal Antibody ◽  
Retrospective Analysis ◽  
Ovarian Tumors ◽  
Murine Monoclonal Antibody ◽  
Ca 125 ◽  
Clinical Value ◽  
Second Look

Between 1986 and 1990 50 patients with ovarian cancer were submitted to a procedure which we called REGAJ - resection guided by antibodies. Using the radiolabeled murine monoclonal antibody OC 125, microscopic ovarian tumors producing CA 125 were detected during second-look surgery by a hand-held probe. Retrospective analysis after 10 years revealed that this procedure resulted in the cure of 4 of 11 patients, who would otherwise have been considered tumor free during second-look surgery and not further treated. Previous problems associated with the method can now be solved so that the clinical value of the procedure should be reconsidered.

Prognosis in Patients With Serous and Mucinous Stage I Borderline Ovarian Tumors

2012 ◽  
Vol 22 (5) ◽  
pp. 770-777 ◽  
Author(s):  
Taejong Song ◽  
Yoo-Young Lee ◽  
Chel Hun Choi ◽  
Tae-Joong Kim ◽  
Jeong-Won Lee ◽  
...  
Keyword(s):  
Ovarian Tumors ◽  
Stage I ◽  
Borderline Ovarian Tumors

scholarly journals Borderline Ovarian Tumors: Fifteen Years’ Experience at a Scottish Tertiary Cancer Center

2018 ◽  
Vol 28 (9) ◽  
pp. 1683-1691 ◽  
Author(s):  
James May ◽  
Karolina Skorupskaite ◽  
Mario Congiu ◽  
Nidal Ghaoui ◽  
Graeme A. Walker ◽  
...  
Keyword(s):  
Malignant Transformation ◽  
Surgical Management ◽  
Early Stage ◽  
Ovarian Tumors ◽  
Ca 125 ◽  
Ovarian Malignancy ◽  
Borderline Ovarian Tumors ◽  
Gynecology And Obstetrics ◽  
Preoperative Serum

ObjectivesSince the recognition of borderline ovarian tumors (BOTs) in the 1970s, the management of this subset of epithelial ovarian tumors has presented a challenge to clinicians. The majority present at an early stage, but their diagnosis is often only made following surgery, hence the heterogeneity of surgical management. Borderline ovarian tumors are morphologically diverse, and their behavior is subsequently also heterogeneous. We aimed to assess recurrence rates and the rate of malignant transformation in patients diagnosed with BOT. Secondary objectives included a review of current management and assessment of tumor markers, stage, cyst dimensions, and the presence of micropapillary features as prognostic indicators of recurrence.MethodsThis retrospective cohort study included all patients treated with BOT between 2000 and 2015 in the southeast region of Scotland. Clinical, surgicopathological, and follow-up data were collated. Data were analyzed with reference to recurrence and malignant transformation.ResultsTwo hundred seventy-five patients underwent treatment for BOT in the study period. Surgical management was highly variable. A diagnosis of recurrent/persistent BOT or ovarian malignancy following initial treatment of BOT was rare, with only 12 (4%) of 275 cases. There were 7 cases (3%) of ovarian malignancy. Advanced International Federation of Gynecology and Obstetrics stage was the most prominent prognostic factor. Elevated preoperative serum CA-125 and the presence of micropapillary features correlated with advanced stage at presentation. With a lack of clear guidance, follow-up was highly variable with a median of 43 months (0–136 months).ConclusionsTo our knowledge, this study is the largest BOT cohort in the United Kingdom. Recurrent disease is rare in optimally staged, completely resected, early-stage BOT, without high-risk features. Caution is needed in women electing not to undergo completion staging after diagnosis and in those opting for a fertility-preserving approach. Thorough informed consent and clear plans for surveillance and follow-up are needed with consideration of delayed completion surgery as appropriate.

Management of stage-I borderline ovarian tumors

1996 ◽  
Vol 54 (1) ◽  
pp. 37-44 ◽  
Author(s):  
H. Ji ◽  
M. Yliskoski ◽  
M. Anttila ◽  
K. Syrjänen ◽  
S. Saarikoski
Keyword(s):  
Ovarian Tumors ◽  
Stage I ◽  
Borderline Ovarian Tumors

Total Inhibin Is a Potential Serum Marker for Epithelial Ovarian Cancer

2007 ◽  
Vol 92 (7) ◽  
pp. 2526-2531 ◽  
Author(s):  
Anastasia Tsigkou ◽  
Daniele Marrelli ◽  
Fernando M. Reis ◽  
Stefano Luisi ◽  
Agnaldo L. Silva-Filho ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Postmenopausal Women ◽  
Serum Marker ◽  
Ovarian Tumors ◽  
Ca 125 ◽  
Surgical Removal ◽  
Specific Marker ◽  
Ovarian Cancers ◽  
Blood Specimens

Abstract Context: Total inhibin is the sum of precursors, subunits, and mature molecules of inhibin, which the normal ovary nearly stops to produce after menopause, whereas ovarian tumors still release. Objective: The aim of the present study was to evaluate whether the serum concentration of total inhibin has the sensitivity/specificity characteristics to become a diagnostic test for epithelial ovarian cancer in postmenopausal women. Design: This was a controlled, cross-sectional study. Setting: The study was conducted at the University of Siena. Patients: Blood specimens were collected from postmenopausal women with: 1) epithelial ovarian cancer, stage II-III (n = 89); 2) benign ovarian tumors (n = 25); 3) breast (n = 10), colon (n = 10), and stomach (n = 10) cancers; and 4) controls (n = 95). In the group of women with epithelial ovarian cancer, blood specimens were also collected after surgical removal of the tumor. In four cases of women with stage IIC mucinous tumor, blood specimens were collected during the follow-up time. Intervention: Total inhibin was measured by a new double-antibody ELISA. Results: Women with epithelial ovarian cancers showed serum total inhibin levels significantly higher than those with benign tumor or with nonovarian tumors or controls (P < 0.001). Patients with serous (n = 40) or mucinous tumors (n = 17) showed the highest total inhibin levels (P < 0.001). At 95% specificity, the total inhibin assay detected 37 of 40 (93%) serous tumors and 16 of 17 (94%) mucinous tumors. When total inhibin was combined with CA-125, all cases of serous and mucinous tumors were detected, and the overall sensitivity for epithelial ovarian cancers was 99% at 95% specificity. A significant decrease of total inhibin levels was shown in women with serous and mucinous carcinoma as result of surgery (P < 0.001). In the four women who were followed up, recurrence was associated to an increase of total inhibin levels. Conclusions: The present data show that total inhibin is a sensitive and specific marker of epithelial ovarian cancers in postmenopausal women. Total inhibin may therefore be combined with CA-125 for noninvasive diagnosis of epithelial ovarian cancer and may also be a useful serum marker to monitor disease-free intervals.

Sign in / Sign up

Export Citation Format

Share Document